BELLUS Health is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Co.'s primary product candidate, BLU-5937, is a selective and potentially antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. Co. is developing BLU-5937 for the treatment of adults with RCC. We show 3 historical shares outstanding datapoints in our BLU shares outstanding history coverage, used to compute BLU market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLU market cap history over the course of time is important for investors
interested in comparing BLU's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLU versus a peer is one thing; comparing
BLU market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLU can fluctuate over the course of history.
With this page we aim to empower investors researching BLU by allowing them to research the BLU market cap history. |
Free BLU Email Alerts:
Video: The Importance of Market Cap
